Market Access
Everything You Need to Know About Market Access in China
Given China’s status as the world’s second most populous nation and an economic powerhouse, ...
Strategies for Combination Therapy in Oncology: Part Two – Working with the “Status Quo”
This is the second article in a three-part series examining the commercial dynamics surrounding ...
Strategies for Combination Therapy in Oncology: Part One – Business as Usual
This is the first in a three-part series examining the commercial dynamics surrounding combination ...
Trends and Challenges in Diabetes Management Devices
During the last 100 years since the discovery of insulin, a hormone that helps ...
Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program
As many in the industry now know, the Inflation Reduction Act (IRA) is the ...
Lessons Learned from CMS’ Alzheimer’s Drug Coverage Decision
The recent wave of Alzheimer’s Disease (AD) drug approvals and promising pivotal trial data ...
Pharma Has a Pull-Through Problem—The Answer is Data
Most market access teams at pharmaceutical and biotech manufacturers have the same problem: evidence ...
The Second Order Effects of the Inflation Reduction Act: What Uncertainties Does Pharma Need to Plan For?
Since passage of the Inflation Reduction Act (IRA) in August 2022, the focus of ...
Consider Adherence, Cognitive Bias, and Artificial Intelligence
Call him Robert. He lives in a rural community, has three chronic conditions, and ...
Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets
Access to medicines have persisting and systemic differences across the globe and within countries. ...
Recent Trends Impacting Funding and Access to Rare Disease Therapies
Funding and access are not new topics of conversation in the rare disease space. ...
New Research Reveals Three Ways Pharma Can Better Prioritize Payer Audiences
The pandemic had a huge impact on the way population health decision-makers (PHDMs) navigate ...
Biosimilars Market Set for Biggest Year Yet in 2023
In perhaps the most significant moment for the U.S. biosimilars market to date, the ...
